论文部分内容阅读
今年一季度,我国医药行业的亏损面大幅度增加,持续亏损和由盈转亏的企业上升到23.2％,为历史最高水平。然而行业的销售收入却同比增长10.9％,利润总额同比增长17.2％。行业亏损面加大,利润总额却实现增长,究其原因是由于一些占权重非常大的企业如西安杨森、中美史克、山东鲁抗、北京双鹤等大型制药集团利润高速增长。与大型制药企业形成鲜明对比的是,中小型制药企业利润上升的比例由60％下
In the first quarter of this year, the loss face of China’s pharmaceutical industry increased significantly, and the number of companies that continued to lose money and turn from loss to profit rose to 23.2%, which was the highest level in history. However, the sales revenue of the industry increased by 10.9% year-on-year, and total profit increased by 17.2% year-on-year. The increase in the loss of profits in the industry and the increase in total profits are due to the rapid growth of large-scale pharmaceutical groups such as Xi’an Janssen, Sino-US SSK, Shandong Lukang, and Beijing Shuanghe. In stark contrast to large-scale pharmaceutical companies, the proportion of profits of small and medium-sized pharmaceutical companies rose by 60%.